CYP2D6 (A300) Polyclonal Antibody

Catalogue Numbers: BS5684-50, BS5684-100

Sizes: 50µl, 100µl

Alternative Name: Cytochrome P450 2D6; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase; CYP2DL1

Product: Rabbit IgG, 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2

Swiss-Prot: P10635

Host: Rabbit

Reactivity: Human, Mouse, Rat

Applications: WB, IHC

All Applications: WB: 1:500~1:1000
IHC: 1:50~1:200

Background: Enhanced CYP2D6 activity has been related to malignancies of the bladder, liver, pharynx, and stomach and, especially, to cigarette-smoking-induced lung cancer. The data suggests that enhanced CYP2D6-mediated metabolism of one or more dietary and other environmental agents, to form a reactive intermediate, plays a role in cancer initiation and/or promotion in various tissues. CYP2D6 polymorphism, which is responsible for the variation in metabolism of debrisoquine 4-hydroxylase, is important in the metabolism of more than 30 drugs and environmental chemicals, including as much as 20% of all commonly prescribed drugs.

Purification and Purity: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).

Storage and Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: CYP2D6 (A300) polyclonal antibody detects endogenous levels of CYP2D6 protein.

Bioworld Molecular Weight: ~ 55 kDa

Note: For research use only, not for use in diagnostic procedure.

Extra Notes: Western blot (WB) analysis of CYP2D6 (A300) polyclonal antibody at 1:500 dilution
Lane 1: MCF-7 cell lysate
Lane 2: NIH-3T3 cell lysate
Lane 3: H9C2 cell lysate

Immunogen: Synthetic peptide, corresponding to amino acids 283-328 of Human CYP2D6.

Conjugate: Unconjugated

Modification: Unmodified